JP2014526562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526562A5 JP2014526562A5 JP2014532075A JP2014532075A JP2014526562A5 JP 2014526562 A5 JP2014526562 A5 JP 2014526562A5 JP 2014532075 A JP2014532075 A JP 2014532075A JP 2014532075 A JP2014532075 A JP 2014532075A JP 2014526562 A5 JP2014526562 A5 JP 2014526562A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- disorder
- superoxide dismutase
- agent according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 35
- 229940124597 therapeutic agent Drugs 0.000 claims 35
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 29
- 108010012715 Superoxide dismutase Proteins 0.000 claims 29
- 239000003446 ligand Substances 0.000 claims 23
- 238000009472 formulation Methods 0.000 claims 17
- 230000003278 mimic effect Effects 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 238000002512 chemotherapy Methods 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 238000001959 radiotherapy Methods 0.000 claims 6
- 230000007935 neutral effect Effects 0.000 claims 5
- 239000000243 solution Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 208000019693 Lung disease Diseases 0.000 claims 3
- 208000032376 Lung infection Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims 3
- 125000003963 dichloro group Chemical group Cl* 0.000 claims 3
- 208000010643 digestive system disease Diseases 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 239000005022 packaging material Substances 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 239000007975 buffered saline Substances 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims 1
- 244000299906 Cucumis sativus var. sativus Species 0.000 claims 1
- 125000002579 carboxylato group Chemical group [O-]C(*)=O 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161539365P | 2011-09-26 | 2011-09-26 | |
| US61/539,365 | 2011-09-26 | ||
| PCT/US2012/056921 WO2013048965A1 (en) | 2011-09-26 | 2012-09-24 | Methods for treatment of diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017172825A Division JP6382416B2 (ja) | 2011-09-26 | 2017-09-08 | 疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526562A JP2014526562A (ja) | 2014-10-06 |
| JP2014526562A5 true JP2014526562A5 (cg-RX-API-DMAC7.html) | 2015-11-12 |
| JP6267638B2 JP6267638B2 (ja) | 2018-01-24 |
Family
ID=47911939
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014532075A Active JP6267638B2 (ja) | 2011-09-26 | 2012-09-24 | 疾患の治療方法 |
| JP2017172825A Active JP6382416B2 (ja) | 2011-09-26 | 2017-09-08 | 疾患の治療方法 |
| JP2018145207A Active JP6736618B2 (ja) | 2011-09-26 | 2018-08-01 | 疾患の治療方法 |
| JP2020121417A Active JP7562125B2 (ja) | 2011-09-26 | 2020-07-15 | 疾患の治療方法 |
| JP2022200192A Active JP7697688B2 (ja) | 2011-09-26 | 2022-12-15 | 疾患の治療方法 |
| JP2025094341A Pending JP2025131753A (ja) | 2011-09-26 | 2025-06-05 | 疾患の治療方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017172825A Active JP6382416B2 (ja) | 2011-09-26 | 2017-09-08 | 疾患の治療方法 |
| JP2018145207A Active JP6736618B2 (ja) | 2011-09-26 | 2018-08-01 | 疾患の治療方法 |
| JP2020121417A Active JP7562125B2 (ja) | 2011-09-26 | 2020-07-15 | 疾患の治療方法 |
| JP2022200192A Active JP7697688B2 (ja) | 2011-09-26 | 2022-12-15 | 疾患の治療方法 |
| JP2025094341A Pending JP2025131753A (ja) | 2011-09-26 | 2025-06-05 | 疾患の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US9149483B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2760874A4 (cg-RX-API-DMAC7.html) |
| JP (6) | JP6267638B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN111467351A (cg-RX-API-DMAC7.html) |
| AU (5) | AU2012316397B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3120505C (cg-RX-API-DMAC7.html) |
| HK (1) | HK1199261A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013048965A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2056675T3 (pl) | 2006-10-12 | 2019-08-30 | Galera Labs, Llc | Metody leczenia zapalenia błony śluzowej jamy ustnej |
| AU2012316397B2 (en) * | 2011-09-26 | 2016-07-21 | Galera Labs, Llc | Methods for treatment of diseases |
| TWI746449B (zh) * | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| CN113416170B (zh) * | 2015-08-11 | 2025-03-25 | 加莱拉实验室有限责任公司 | 具有口服生物利用率的五氮杂大环状环络合物 |
| SG11201809606YA (en) | 2016-05-03 | 2018-11-29 | Galera Labs Llc | Combination therapy for cancer treatment |
| AU2017318718B2 (en) * | 2016-09-01 | 2023-06-29 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound |
| CN110520107A (zh) * | 2017-02-15 | 2019-11-29 | 加莱拉实验室有限责任公司 | 用于局部肠递送的五氮杂大环状环配合物 |
| US11246950B2 (en) | 2017-04-13 | 2022-02-15 | Galera Labs, Llc | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| WO2019152661A1 (en) * | 2018-01-31 | 2019-08-08 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent |
| EP4041253A4 (en) * | 2019-10-10 | 2023-11-01 | Galera Labs, LLC | PRODUCTION PROCESS FOR AQUEOUS FORMULATION OF A COORDINATION COMPLEX CONTAINING MANGANESE, FORMULATION AND TREATMENT PROCESS |
| WO2021163397A1 (en) * | 2020-02-13 | 2021-08-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of avasopasem manganese and process for preparation thereof |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001212A (en) | 1973-10-03 | 1977-01-04 | E. I. Du Pont De Nemours And Company | Macrocyclic polyamines |
| US3930867A (en) | 1974-01-07 | 1976-01-06 | E. I. Du Pont De Nemours And Company | Macrocyclic polyamines as sensitizers for silver halide emulsions |
| JPS61226751A (ja) | 1985-03-30 | 1986-10-08 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真感光材料用処理液及びその処理方法 |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5096724A (en) | 1988-06-03 | 1992-03-17 | Aquanautics Corporation | Methods, compositions, and systems for ligand extraction |
| GB9001245D0 (en) | 1990-01-19 | 1990-03-21 | Salutar Inc | Compounds |
| CA2072934C (en) | 1991-07-19 | 2007-08-28 | Karl William Aston | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| DE69224839T2 (de) | 1991-07-19 | 1998-10-08 | Monsanto Co | Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren. |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| CA2188530A1 (en) | 1994-04-22 | 1995-11-02 | John Charles Alexander | Diagnostic image analysis with metal complexes |
| US6245758B1 (en) | 1994-05-13 | 2001-06-12 | Michael K. Stern | Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor |
| JPH0840941A (ja) | 1994-07-29 | 1996-02-13 | Kanegafuchi Chem Ind Co Ltd | 炎症性腸疾患治療製剤 |
| US6525041B1 (en) | 1995-06-06 | 2003-02-25 | Pharmacia Corporation | Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| EP0844889A1 (en) | 1995-08-17 | 1998-06-03 | Monsanto Company | Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands |
| WO1997006830A1 (en) | 1995-08-17 | 1997-02-27 | Monsanto Company | Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands |
| EP0844886A2 (en) * | 1995-08-17 | 1998-06-03 | Monsanto Company | Bioconjugates of manganese complexes and their application as catalysts |
| US6214817B1 (en) | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| US20050171198A1 (en) | 1997-06-20 | 2005-08-04 | Metaphore Pharmaceuticals, Inc. | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease |
| US20020128248A1 (en) | 1997-06-20 | 2002-09-12 | Metaphore Pharmaceuticals, Inc | SODm therapy for prevention and/or treatment of inflammatory disease |
| US20060270639A1 (en) | 1997-06-20 | 2006-11-30 | Daniela Salvemini | Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs |
| US6180620B1 (en) | 1997-06-20 | 2001-01-30 | G.D. Searle & Co. | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
| JP2991172B2 (ja) | 1997-10-24 | 1999-12-20 | 日本電気株式会社 | 半導体装置 |
| ES2198767T3 (es) | 1997-11-03 | 2004-02-01 | Duke University | Porfirinas sustituidas. |
| GB9817845D0 (en) | 1998-08-17 | 1998-10-14 | Glaxo Group Ltd | Chemical compounds |
| US6040330A (en) | 1999-01-08 | 2000-03-21 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of taxanes |
| CA2374472A1 (en) | 1999-05-27 | 2000-12-07 | Monsanto Company | Biomaterials modified with superoxide dismutase mimics |
| US6448239B1 (en) | 1999-06-03 | 2002-09-10 | Trustees Of Princeton University | Peroxynitrite decomposition catalysts and methods of use thereof |
| WO2000078316A1 (en) | 1999-06-23 | 2000-12-28 | Bernstein Eric F | Use of nitroxides in wound healing and in the prevention of photodamage |
| CA2399293C (en) | 2000-02-08 | 2012-01-03 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| AU2000265525A1 (en) | 2000-08-29 | 2002-03-13 | Mepha Ag | Medicament for treating intestinal diseases |
| US6589948B1 (en) * | 2000-11-28 | 2003-07-08 | Eukarion, Inc. | Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
| US7166910B2 (en) | 2000-11-28 | 2007-01-23 | Knowles Electronics Llc | Miniature silicon condenser microphone |
| US20020072512A1 (en) | 2000-12-08 | 2002-06-13 | Metaphore Pharmaceuticals, Inc | Method of preventing and treating HIV-mediated central nervous system damage |
| US20050175580A1 (en) | 2001-01-05 | 2005-08-11 | Daniela Salvemini | Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines |
| JP2004520380A (ja) * | 2001-01-19 | 2004-07-08 | ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター | 癌治療本出願は、２００１年１月１９日に出願の仮出願番号第６０／２６２，３９０号の優先権を主張し、その全ての内容は、参照により本願明細書に援用したものとする。 |
| EP1353655A2 (en) | 2001-01-26 | 2003-10-22 | Metaphore Pharmaceuticals Inc. | Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes |
| RU2003129271A (ru) | 2001-03-02 | 2005-03-20 | Метафор Фармасьютикалз, Инк. (Us) | Хроматография комплексов металлов |
| US20040137638A1 (en) | 2002-03-04 | 2004-07-15 | Slomczynska Urszula J. | Chromatography of metal complexes |
| WO2002100395A1 (en) | 2001-06-08 | 2002-12-19 | Genzyme Corporation | Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers |
| US20040132706A1 (en) | 2001-10-05 | 2004-07-08 | Daniela Salvemini | Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension |
| IL161686A0 (en) | 2001-11-01 | 2004-09-27 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| ES2319399T3 (es) * | 2001-12-14 | 2009-05-07 | Alcon, Inc. | Compuestos mimeticos de la superoxido-dismutasa para el tratamiento de trastornos y enfermedades oculares. |
| AU2003229923A1 (en) | 2002-04-16 | 2003-11-03 | Isis Innovation Limited | Curcumin for the prevention and/or treatment of tissue damage |
| US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| US6781231B2 (en) | 2002-09-10 | 2004-08-24 | Knowles Electronics Llc | Microelectromechanical system package with environmental and interference shield |
| US6798047B1 (en) | 2002-12-26 | 2004-09-28 | Amkor Technology, Inc. | Pre-molded leadframe |
| WO2005042718A2 (en) | 2003-10-31 | 2005-05-12 | Metaphore Pharmaceuticals, Inc. | Compositions and methods for treating, preventing, reversing and inhibiting pain |
| FR2863892B1 (fr) | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
| US7510710B2 (en) | 2004-01-08 | 2009-03-31 | The Regents Of The University Of Colorado | Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor |
| KR20060135922A (ko) | 2004-03-29 | 2006-12-29 | 이노텍 파마슈티컬스 코포레이션 | 피리딜 치환된 포르피린 화합물 및 이의 사용 방법 |
| US7262498B2 (en) | 2004-10-19 | 2007-08-28 | Hewlett-Packard Development Company, L.P. | Assembly with a ring and bonding pads formed of a same material on a substrate |
| US20070148154A1 (en) | 2004-12-17 | 2007-06-28 | Universite Rene Descartes (Paris V) | Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs |
| US8217166B2 (en) | 2005-05-05 | 2012-07-10 | Galera Therapeutics, Llc | Polyethylene glycolated superoxide dismutase mimetics |
| WO2006083508A2 (en) | 2005-01-10 | 2006-08-10 | Metaphore Pharmaceuticals Inc. | Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs |
| WO2006078713A2 (en) | 2005-01-19 | 2006-07-27 | Metaphore Pharmaceuticals, Inc. | Methotrexate combinations for treating inflammatory diseases |
| AU2006230292A1 (en) | 2005-03-31 | 2006-10-05 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
| CN2870352Y (zh) | 2005-12-23 | 2007-02-14 | 瑞声声学科技(深圳)有限公司 | 微机电系统传声器扣合式封装结构 |
| EP2020998A4 (en) | 2006-05-23 | 2010-07-21 | Univ Utah Res Found | Compositions and methods for the inhibition of endothelial nitric oxide synthase activity |
| US20080139525A1 (en) | 2006-08-31 | 2008-06-12 | The Brigham And Women's Hospital, Inc. | Antioxidant therapies |
| US20080161324A1 (en) | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| PL2056675T3 (pl) * | 2006-10-12 | 2019-08-30 | Galera Labs, Llc | Metody leczenia zapalenia błony śluzowej jamy ustnej |
| TWI333264B (en) | 2007-01-10 | 2010-11-11 | Advanced Semiconductor Eng | Packaging structure and method of mems microphone |
| EP2190453A2 (en) * | 2007-09-11 | 2010-06-02 | Mondobiotech Laboratories AG | Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents |
| EP2259776A4 (en) | 2008-02-29 | 2011-03-16 | Eagle Pharmaceuticals Inc | USEFUL TOPOTECAN SOLUTIONS |
| WO2009134616A2 (en) | 2008-04-15 | 2009-11-05 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| CA2724550C (en) | 2008-05-22 | 2017-01-03 | Kereos, Inc. | Combination antitumor therapy |
| KR20130049775A (ko) | 2010-03-12 | 2013-05-14 | 애브비 바이오테라퓨틱스 인크. | Ｃｔｌａ４ 단백질 및 이의 용도 |
| US20120207687A1 (en) | 2011-01-14 | 2012-08-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Topical formulations of targeted nitroxide agents |
| AU2012316397B2 (en) | 2011-09-26 | 2016-07-21 | Galera Labs, Llc | Methods for treatment of diseases |
| US9238659B2 (en) | 2012-11-19 | 2016-01-19 | The University Of Hong Kong | Method of using binuclear gold (I) compounds for cancer treatment |
| CN113416170B (zh) | 2015-08-11 | 2025-03-25 | 加莱拉实验室有限责任公司 | 具有口服生物利用率的五氮杂大环状环络合物 |
| SG11201809606YA (en) | 2016-05-03 | 2018-11-29 | Galera Labs Llc | Combination therapy for cancer treatment |
| AU2017318718B2 (en) | 2016-09-01 | 2023-06-29 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound |
| WO2018125862A1 (en) | 2016-12-27 | 2018-07-05 | Soon Kap Hahn | Prevention of local tumor recurrence following surgery using sustained and/or delayed release of medicaments contained in micro-particles |
| CN110520107A (zh) | 2017-02-15 | 2019-11-29 | 加莱拉实验室有限责任公司 | 用于局部肠递送的五氮杂大环状环配合物 |
| CA3059581A1 (en) | 2017-04-13 | 2018-10-18 | Galera Labs, Llc | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| US11246950B2 (en) | 2017-04-13 | 2022-02-15 | Galera Labs, Llc | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| WO2019152661A1 (en) | 2018-01-31 | 2019-08-08 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent |
-
2012
- 2012-09-24 AU AU2012316397A patent/AU2012316397B2/en not_active Ceased
- 2012-09-24 US US13/625,617 patent/US9149483B2/en active Active
- 2012-09-24 CA CA3120505A patent/CA3120505C/en active Active
- 2012-09-24 CN CN202010082500.XA patent/CN111467351A/zh active Pending
- 2012-09-24 CA CA2849456A patent/CA2849456C/en active Active
- 2012-09-24 WO PCT/US2012/056921 patent/WO2013048965A1/en not_active Ceased
- 2012-09-24 CN CN201280053322.1A patent/CN103906756B/zh active Active
- 2012-09-24 JP JP2014532075A patent/JP6267638B2/ja active Active
- 2012-09-24 EP EP20120835035 patent/EP2760874A4/en active Pending
- 2012-09-24 HK HK14112775.0A patent/HK1199261A1/xx unknown
-
2015
- 2015-08-27 US US14/837,831 patent/US10137133B2/en active Active
-
2016
- 2016-10-20 AU AU2016247160A patent/AU2016247160B2/en not_active Ceased
-
2017
- 2017-09-08 JP JP2017172825A patent/JP6382416B2/ja active Active
-
2018
- 2018-08-01 JP JP2018145207A patent/JP6736618B2/ja active Active
- 2018-10-31 US US16/176,958 patent/US10493081B2/en active Active
-
2019
- 2019-02-27 AU AU2019201392A patent/AU2019201392B2/en active Active
- 2019-11-12 US US16/680,844 patent/US11826373B2/en active Active
-
2020
- 2020-07-15 JP JP2020121417A patent/JP7562125B2/ja active Active
- 2020-10-05 AU AU2020244613A patent/AU2020244613C1/en active Active
-
2022
- 2022-12-15 JP JP2022200192A patent/JP7697688B2/ja active Active
-
2023
- 2023-03-31 AU AU2023201978A patent/AU2023201978A1/en not_active Abandoned
- 2023-10-18 US US18/381,524 patent/US20250017944A1/en not_active Abandoned
-
2025
- 2025-06-05 JP JP2025094341A patent/JP2025131753A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526562A5 (cg-RX-API-DMAC7.html) | ||
| JP2018184465A5 (cg-RX-API-DMAC7.html) | ||
| JP2018035162A5 (cg-RX-API-DMAC7.html) | ||
| US12059397B2 (en) | Calcium lactate compositions and methods of use | |
| ES2424476T3 (es) | Nanopartículas cargadas con fármaco antitumoral quimioterápico | |
| JP2020183416A5 (cg-RX-API-DMAC7.html) | ||
| RU2010114042A (ru) | Применение пептида в качестве терапевтического средства | |
| CN109970987B (zh) | Mof材料、纳米载药材料、药物组合物及其应用 | |
| WO2007134534A1 (fr) | Solution aqueuse de composition pharmaceutique de 20(r)-ginsenoside rg3 et procédé correspondant | |
| JP2014088444A5 (cg-RX-API-DMAC7.html) | ||
| JP2014521658A5 (cg-RX-API-DMAC7.html) | ||
| JP2015524444A5 (cg-RX-API-DMAC7.html) | ||
| RU2010113989A (ru) | Применение пептида в качестве терапевтического средства | |
| JP2019512495A5 (cg-RX-API-DMAC7.html) | ||
| RU2017115990A (ru) | Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии | |
| JP2013542263A5 (cg-RX-API-DMAC7.html) | ||
| JP6029808B2 (ja) | 併用療法における（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の使用方法 | |
| CN103370066B (zh) | 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法 | |
| CN109498627A (zh) | 一种治疗肿瘤的药物组合物及其应用 | |
| RU2358730C2 (ru) | Производное эпотилона для лечения гепатомы и других раковых заболеваний | |
| JP2012525358A5 (cg-RX-API-DMAC7.html) | ||
| WO2015153820A1 (en) | Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer | |
| JP2014502608A5 (cg-RX-API-DMAC7.html) | ||
| TW202128151A (zh) | 癌症治療方法 | |
| FI3654989T3 (fi) | Kladribiinin käyttö neuromuskulaarisen autoimmuunisairauden hoitoon |